
|Slideshows|September 25, 2021
Endocrine Month in Review: September 2021
September's endocrine month in review features news related to diabetes, polycystic ovary syndrome, warnings from the FDA and FTC, and a column from Dr. Paul Thompson.
Advertisement
Top Stories of September 2021:
North American Menopause Society Releases Updated Osteoporosis Guidance
The organization's first update since their 2010 position statement, the osteoporosis position statement reflects more than a decade of advances in knowledge related to diagnosis and management of osteoporosis.FDA Warns 10 Companies For Illegally Marketing Supplements Claiming to Treat Diabetes
The FDA and FTC posted warnings to 10 companies for violating the Federal Food, Drug, and Cosmetic Act by selling dietary supplements claiming to cure, treat, mitigate, or prevent diabetes.Patients with Diabetes More Likely to Experience Sexual Dysfunction
New data describes risk factors associated with increased prevalence of sexual dysfunction among patients with type 1 and type 2 diabetes.Why Cardiologists Should Become Diabetologists, With Paul D. Thompson, MD
Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.Treating Polycystic Ovary Syndrome Costs $8 Billion in US Annually
A meta-analysis builds upon previous research and provides new insight into the total costs of diagnosis and treating PCOS as well as the costs of treating PCOS-related comorbidities.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
4
Ketone Monitoring in Diabetes: Making The Case For When and How to Test
5

























































